1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 13 OCTOBER 2014

Cancer Drug News 13 OCTOBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 28 pages

Industry Trend Analysis - Personalised Therapy Becoming A Mainstay In Cancer Treatment
Industry Brief - FDA Approves Velcade For Previously Untreated Patients With MCL
Industry Brief - BMS/Pharmacyclics/Janssen Enter Clinical Trial Collaboration For Opdivo/Imbruvica
Industry Brief - PRAC Recommends No Change To Iclusig's Approved Indication In Europe
Industry Brief - DSMB Recommends Continuation Of Sapacitabine Phase III Trial In AML
Industry Trend Analysis - New Wave Of ALK Inhibitors Set To Enter Market
Industry Brief - Novartis Enters Collaboration To Evaluate Opdivo In Combination Treatments For NSCLC
Industry Brief - Resminostat Phase II Study Initiated In Asian NSCLC Patients
Industry Brief - Zytiga Plus Prednisone Prolongs OS In Phase III MCRPCA Study
Industry Brief - Ipsen Reports Positive Results From SC Decapeptyl Phase III PCA Study
Industry Brief - First Patient Enrolled In Fosbretabulin/Pazopanib Phase Ib/II Study In Recurrent OC
Industry Brief - Halozyme Secures US Patent Covering Companion Diagnostic For PEGPH20
Industry Brief - Delcath Commences US Phase II Study Of Melphalan/HDS In HCC
Industry Brief - Pinnacle Reports European Site Initiation For Photofrin Phase III Bile Duct Cancer Trial
Industry Brief - Novartis Reports Final Results From Afinitor Phase III Trial In Pancreatic NET
Industry Brief - FDA Grants ODD To DNAtrix' DNX-2401 For Treating Malignant Glioma
Industry Brief - Medigene Secures Australian Patent For TCR-Modified T-Cell Immunotherapy
Industry Trend Analysis - Roche To Provide Competitor To GSK's Melanoma Combination
Industry Brief - ARIAD/Bellicum Restructure Licence Agreement For Cell-Signalling Technology
Industry Brief - OBM Signs Further Contracts With Novartis
Industry Brief - Galena Receives US Patent Allowance For NeuVax Combination
Industry Trend Analysis - Immunotherapy-Targeted Research Data Highlighted At ESMO 2014
Industry Brief - Vernalis Licenses Vipadenant To Redox For Use In Immuno-Oncology
Industry Trend Analysis - Akynzeo To Compete With Merck's Emend In CINV Prevention
Industry Brief - Imperial Innovations Invests GBP1.85mn In Kesios Therapeutics
Industry Brief - Onxeo Reaches Second Milestone Of BPIFrance Grant For Livatag Development
Industry Brief - Rich Pharmaceuticals Raises Funds For Phase II Trials In AML

Table Of Contents

Cancer Drug News 13 OCTOBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.